Article

Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune Diseases

2024-01-24

Abstract excerpt

<h4>ABSTRACT</h4> Apheresis, a conventional starting point for manufacturing chimeric antigen receptor (CAR) T-cell therapy, poses challenges due to the length and invasiveness of the procedure, the high demand for and limited quantity of apheresis beds, and additional resource constraints at collection centers. Furthermore, traditional CAR T-cell manufacturing often involves extended cell culture periods, leadin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3bd63c33-7df9-589e-a2a6-235312aab6e8
DOI: 10.1101/2024.01.24.576713

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune DiseasesDOI 10.1101/2024.01.24.576713Read

Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi ArabiaSemantic proximity Read

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Semantic proximity Read

A closed, autologous bioprocess optimized for TCR-T cell therapiesSemantic proximity Read

Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.Semantic proximity Read

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.Semantic proximity Read

A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.Semantic proximity Read

Optimized Multiple Amplification Protocol for the Production of Allogeneic Human Vγ9Vδ2 T Lymphocytes for Adoptive Cell Transfer ImmunotherapySemantic proximity Read

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.Semantic proximity Read

Allogeneic CAR-T Cells: Engineering Around Host ImmunitySemantic proximity Read

Anti-CD19 CAR-T cell therapy for acquired hemophilia ASemantic proximity Read

Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.Semantic proximity Read

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read